Adipose tissue-derived mesenchymal stromal cells for clinical application: An efficient isolation approach

D. Lisini, S. Nava, S. Pogliani, M. A. Avanzini, E. Lenta, G. Bedini, M. Mantelli, L. Pecciarini, S. Croce, G. Boncoraglio, R. Maccario, E. A. Parati, S. Frigerio

Research output: Contribution to journalArticle

Abstract

Purpose of the study: Mesenchymal stromal cells (MSCs) are considered a promising tool for cell therapy approaches. The translation of research-based cell culture protocols into procedures that comply with Good Manufacturing Practice (GMP) is critical. The aim of this study was to design a new method for the expansion of MSCs from Adipose Tissue (AT-MSCs) in compliance with GMP, without enzymatic tissue digestion and without the use of animal proteins as source of growth factors. Patients and methods: MSCs were expanded from 10 periumbilical biopsies. Our new isolation approach is based on: (1) disruption of AT with an automated, closed system; (2) use of GMP-grade medium without the addition of fetal bovine serum or platelet lysate; (3) use of human recombinant Trypsin. AT-MSCs cultured in α-MEM and minced by scalpel were used as control. Results: It was possible to expand MSCs from all the AT-samples for at least eight passages. MSCs displayed the typical spindle-shape morphology, a high viability, multilineage differentiation potential and high expression levels of the typical MSC-specific surface antigens and genes. Compared to standard method, MSCs obtained with the new method showed higher yield, up to passage 6, and higher purity in terms of percentage of CD34 and CD45 markers. All AT-MSCs exhibit in vitro immunosuppressive capacity and possess a normal karyotype. Conclusions: Our data clearly demonstrate that our new approach permits to generate AT-MSCs fully compliant for therapeutic use and better at least in terms of quantity and purity than those obtained with the standard method.

Original languageEnglish
JournalCurrent Research in Translational Medicine
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Mesenchymal Stromal Cells
Adipose Tissue
Tissue
Biopsy
Surface Antigens
Immunosuppressive Agents
Platelets
Cell culture
Trypsin
Intercellular Signaling Peptides and Proteins
Animals
Genes
Proteins
Therapeutic Uses
Cell- and Tissue-Based Therapy
Karyotype
Digestion
Blood Platelets
Cell Culture Techniques

Keywords

  • Adipose tissue
  • Cell isolation
  • Cell therapy
  • GMPs
  • MSCs

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{3084160429ec4ae8914ce523848d2610,
title = "Adipose tissue-derived mesenchymal stromal cells for clinical application: An efficient isolation approach",
abstract = "Purpose of the study: Mesenchymal stromal cells (MSCs) are considered a promising tool for cell therapy approaches. The translation of research-based cell culture protocols into procedures that comply with Good Manufacturing Practice (GMP) is critical. The aim of this study was to design a new method for the expansion of MSCs from Adipose Tissue (AT-MSCs) in compliance with GMP, without enzymatic tissue digestion and without the use of animal proteins as source of growth factors. Patients and methods: MSCs were expanded from 10 periumbilical biopsies. Our new isolation approach is based on: (1) disruption of AT with an automated, closed system; (2) use of GMP-grade medium without the addition of fetal bovine serum or platelet lysate; (3) use of human recombinant Trypsin. AT-MSCs cultured in α-MEM and minced by scalpel were used as control. Results: It was possible to expand MSCs from all the AT-samples for at least eight passages. MSCs displayed the typical spindle-shape morphology, a high viability, multilineage differentiation potential and high expression levels of the typical MSC-specific surface antigens and genes. Compared to standard method, MSCs obtained with the new method showed higher yield, up to passage 6, and higher purity in terms of percentage of CD34 and CD45 markers. All AT-MSCs exhibit in vitro immunosuppressive capacity and possess a normal karyotype. Conclusions: Our data clearly demonstrate that our new approach permits to generate AT-MSCs fully compliant for therapeutic use and better at least in terms of quantity and purity than those obtained with the standard method.",
keywords = "Adipose tissue, Cell isolation, Cell therapy, GMPs, MSCs",
author = "D. Lisini and S. Nava and S. Pogliani and Avanzini, {M. A.} and E. Lenta and G. Bedini and M. Mantelli and L. Pecciarini and S. Croce and G. Boncoraglio and R. Maccario and Parati, {E. A.} and S. Frigerio",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.retram.2018.06.002",
language = "English",
journal = "Current Research in Translational Medicine",
issn = "2452-3186",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Adipose tissue-derived mesenchymal stromal cells for clinical application

T2 - An efficient isolation approach

AU - Lisini, D.

AU - Nava, S.

AU - Pogliani, S.

AU - Avanzini, M. A.

AU - Lenta, E.

AU - Bedini, G.

AU - Mantelli, M.

AU - Pecciarini, L.

AU - Croce, S.

AU - Boncoraglio, G.

AU - Maccario, R.

AU - Parati, E. A.

AU - Frigerio, S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of the study: Mesenchymal stromal cells (MSCs) are considered a promising tool for cell therapy approaches. The translation of research-based cell culture protocols into procedures that comply with Good Manufacturing Practice (GMP) is critical. The aim of this study was to design a new method for the expansion of MSCs from Adipose Tissue (AT-MSCs) in compliance with GMP, without enzymatic tissue digestion and without the use of animal proteins as source of growth factors. Patients and methods: MSCs were expanded from 10 periumbilical biopsies. Our new isolation approach is based on: (1) disruption of AT with an automated, closed system; (2) use of GMP-grade medium without the addition of fetal bovine serum or platelet lysate; (3) use of human recombinant Trypsin. AT-MSCs cultured in α-MEM and minced by scalpel were used as control. Results: It was possible to expand MSCs from all the AT-samples for at least eight passages. MSCs displayed the typical spindle-shape morphology, a high viability, multilineage differentiation potential and high expression levels of the typical MSC-specific surface antigens and genes. Compared to standard method, MSCs obtained with the new method showed higher yield, up to passage 6, and higher purity in terms of percentage of CD34 and CD45 markers. All AT-MSCs exhibit in vitro immunosuppressive capacity and possess a normal karyotype. Conclusions: Our data clearly demonstrate that our new approach permits to generate AT-MSCs fully compliant for therapeutic use and better at least in terms of quantity and purity than those obtained with the standard method.

AB - Purpose of the study: Mesenchymal stromal cells (MSCs) are considered a promising tool for cell therapy approaches. The translation of research-based cell culture protocols into procedures that comply with Good Manufacturing Practice (GMP) is critical. The aim of this study was to design a new method for the expansion of MSCs from Adipose Tissue (AT-MSCs) in compliance with GMP, without enzymatic tissue digestion and without the use of animal proteins as source of growth factors. Patients and methods: MSCs were expanded from 10 periumbilical biopsies. Our new isolation approach is based on: (1) disruption of AT with an automated, closed system; (2) use of GMP-grade medium without the addition of fetal bovine serum or platelet lysate; (3) use of human recombinant Trypsin. AT-MSCs cultured in α-MEM and minced by scalpel were used as control. Results: It was possible to expand MSCs from all the AT-samples for at least eight passages. MSCs displayed the typical spindle-shape morphology, a high viability, multilineage differentiation potential and high expression levels of the typical MSC-specific surface antigens and genes. Compared to standard method, MSCs obtained with the new method showed higher yield, up to passage 6, and higher purity in terms of percentage of CD34 and CD45 markers. All AT-MSCs exhibit in vitro immunosuppressive capacity and possess a normal karyotype. Conclusions: Our data clearly demonstrate that our new approach permits to generate AT-MSCs fully compliant for therapeutic use and better at least in terms of quantity and purity than those obtained with the standard method.

KW - Adipose tissue

KW - Cell isolation

KW - Cell therapy

KW - GMPs

KW - MSCs

UR - http://www.scopus.com/inward/record.url?scp=85051366933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051366933&partnerID=8YFLogxK

U2 - 10.1016/j.retram.2018.06.002

DO - 10.1016/j.retram.2018.06.002

M3 - Article

AN - SCOPUS:85051366933

JO - Current Research in Translational Medicine

JF - Current Research in Translational Medicine

SN - 2452-3186

ER -